‘Investor Meet Company’ presentation on 20 March

Summary by AI ^BETAClose X

ImmuPharma PLC will host a live presentation on the 'Investor Meet Company' platform on Friday, March 20, 2026, at 12:00 GMT, featuring its CEO, CSO, and COO. This presentation will discuss the company's announcement from March 17, 2026, which covered an update on P140, the accelerated development of Kapiglucagon for Type 1 Diabetes, and a subscription and WRAP retail offer aiming to raise up to £7.5 million. No new material will be presented, and questions can be submitted in advance or during the meeting.

Disclaimer*

Immupharma PLC

18 March 2026

18 March 2026 | RNS REACH

ImmuPharma PLC

("ImmuPharma" or the "Company")

ImmuPharma to present live on 'Investor Meet Company' platform
Friday 20 March 2026 @ 12:00 (GMT)

ImmuPharma PLC (LSE AIM:), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics is pleased to announce that ImmuPharma's Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation relating to the Company's announcement, released on Tuesday 17 March 2026, titled:

P140 Update - remains on track for licensing deal in 2026

Accelerated Development of Kapiglucagon for Type 1 Diabetes

Subscription & WRAP Retail Offer to raise up to £7.5 million

https://www.immupharma.co.uk/investors/regulatory-news/

The live presentation, via the 'Investor Meet Company' platform, will be held on Friday 20 March 2026 @ 12:00 (GMT).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard until 19 March 2026, 09:00am (GMT), or at any time during the live meeting. No new material will be shared at this presentation.

Investors can sign up to Investor Meet Company for free and add to meet ImmuPharma PLC via: via: https://www.investormeetcompany.com/immupharma-plc/register.

Investors who already follow ImmuPharma PLC on the Investor Meet Company platform, will automatically be invited.

The presentation will also be available post the live meeting, on ImmuPharma's website: https://www.immupharma.co.uk/updates/interviews/.

Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer and Chairman Lisa Baderoon, Head of Investor Relations	+44 (0) 207 206 2650 + 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 3550 +44 (0) 203 650 3650/51 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Investor Meet Company

Investor Meet Company provides a digital platform that enables individual investors and wealth managers to access live, interactive presentations by UK-listed companies, regardless of their shareholding, size or location. For more information go to: https://www.investormeetcompany.com.

About RNS REACH Announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END